State Street Corp Makes New $866,000 Investment in Alumis Inc. (NASDAQ:ALMS)

State Street Corp purchased a new position in shares of Alumis Inc. (NASDAQ:ALMS) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 81,059 shares of the company’s stock, valued at approximately $866,000.

Several other large investors also recently modified their holdings of ALMS. Samsara BioCapital LLC bought a new position in Alumis during the third quarter worth $34,886,000. SR One Capital Management LP acquired a new position in Alumis during the 2nd quarter worth approximately $26,067,000. Yu Fan bought a new position in Alumis in the second quarter worth approximately $10,502,000. Ally Bridge Group NY LLC acquired a new stake in Alumis in the second quarter valued at approximately $8,229,000. Finally, Towerview LLC increased its holdings in shares of Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after acquiring an additional 70,000 shares in the last quarter.

Alumis Stock Performance

ALMS opened at $8.22 on Friday. Alumis Inc. has a fifty-two week low of $7.46 and a fifty-two week high of $13.53. The firm’s 50-day moving average price is $9.55.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ALMS. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Alumis in a report on Friday, December 20th. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, Robert W. Baird assumed coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Alumis has an average rating of “Buy” and an average target price of $26.83.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.